[23/05] Bell Potter maintains a buy rating on MedAdvisor (ASX:MDR) and has increased its 12-month price target to $0.49. The buy rating is maintained by Bell Potter following the release of a positive trading update including revenue levels of $120m-$123m, implying 22% to 26% growth on the prior corresponding period and an EBITDA of $6.8m-$7.6m following a loss of $3m in its prior corresponding period. This has increased revenue forecasts in FY24/25/26, hence the buy rating is maintained.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.35M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12500 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 10000 | 1 |
View Market Depth
| Last trade - 07.00am 17/06/2025 (20 minute delay) ? |
| MDR (ASX) Chart |
Day chart unavailable